HRP20110458T1 - Inhibitori rna-ovisne rna-polimeraze iz virusa hepatitisa c, te pripravci i liječenje u kojem se koriste - Google Patents
Inhibitori rna-ovisne rna-polimeraze iz virusa hepatitisa c, te pripravci i liječenje u kojem se koriste Download PDFInfo
- Publication number
- HRP20110458T1 HRP20110458T1 HR20110458T HRP20110458T HRP20110458T1 HR P20110458 T1 HRP20110458 T1 HR P20110458T1 HR 20110458 T HR20110458 T HR 20110458T HR P20110458 T HRP20110458 T HR P20110458T HR P20110458 T1 HRP20110458 T1 HR P20110458T1
- Authority
- HR
- Croatia
- Prior art keywords
- ethyl
- methyl
- triazolo
- cyclopentyl
- pyran
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims 4
- 239000003112 inhibitor Substances 0.000 title claims 3
- 241000711549 Hepacivirus C Species 0.000 title claims 2
- 108060004795 Methyltransferase Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- -1 -OR6 Chemical group 0.000 claims abstract 30
- 150000001875 compounds Chemical class 0.000 claims abstract 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 26
- 150000003839 salts Chemical class 0.000 claims abstract 17
- 239000012453 solvate Substances 0.000 claims abstract 17
- 229910052736 halogen Inorganic materials 0.000 claims abstract 7
- 150000002367 halogens Chemical class 0.000 claims abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 4
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims abstract 2
- XTCSVDSGUHHIRY-UHFFFAOYSA-N 2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-[2-(5-ethylpyridin-3-yl)ethyl]-4-hydroxy-3h-pyran-6-one Chemical compound CCC1=CN=CC(CCC2(OC(=O)C(CC3=NN4C(C)=CC(C)=NC4=N3)=C(O)C2)C2CCCC2)=C1 XTCSVDSGUHHIRY-UHFFFAOYSA-N 0.000 claims abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 239000001257 hydrogen Substances 0.000 claims abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 24
- SLVAPEZTBDBAPI-UHFFFAOYSA-N 2-cyclopentyl-2-[2-(2,6-diethylpyridin-4-yl)ethyl]-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3h-pyran-6-one Chemical compound CCC1=NC(CC)=CC(CCC2(OC(=O)C(CC3=NN4C(C)=CC(C)=NC4=N3)=C(O)C2)C2CCCC2)=C1 SLVAPEZTBDBAPI-UHFFFAOYSA-N 0.000 claims 11
- HHXVQUXEUPSTEC-UHFFFAOYSA-N 2-[2-[2,6-bis(2,2,2-trifluoroethyl)pyridin-4-yl]ethyl]-2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3h-pyran-6-one Chemical compound N1=C2N=C(C)C=C(C)N2N=C1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCC1=CC(CC(F)(F)F)=NC(CC(F)(F)F)=C1 HHXVQUXEUPSTEC-UHFFFAOYSA-N 0.000 claims 7
- SHNZPCPBLPOEEZ-UHFFFAOYSA-N 2-cyclopentyl-2-[2-(5-ethoxy-2-ethylpyridin-4-yl)ethyl]-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-3h-pyran-6-one Chemical compound CCOC1=CN=C(CC)C=C1CCC1(C2CCCC2)OC(=O)C(CC2=NN3C=C(C)C=NC3=N2)=C(O)C1 SHNZPCPBLPOEEZ-UHFFFAOYSA-N 0.000 claims 7
- CDOUPZXWEKOMRI-UHFFFAOYSA-N 2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-[2-(5-ethoxy-2-ethylpyridin-4-yl)ethyl]-4-hydroxy-3h-pyran-6-one Chemical compound CCOC1=CN=C(CC)C=C1CCC1(C2CCCC2)OC(=O)C(CC2=NN3C(C)=CC(C)=NC3=N2)=C(O)C1 CDOUPZXWEKOMRI-UHFFFAOYSA-N 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 claims 1
- QSZNBUCBMYJWFQ-UHFFFAOYSA-N 1-[2-[2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3h-pyran-2-yl]ethyl]-5-ethylpyridin-2-one Chemical compound C1=C(CC)C=CC(=O)N1CCC1(C2CCCC2)OC(=O)C(CC2=NN3C(C)=CC(C)=NC3=N2)=C(O)C1 QSZNBUCBMYJWFQ-UHFFFAOYSA-N 0.000 claims 1
- OBJZLLQBRVVCFZ-UHFFFAOYSA-N 2-[2-(6-amino-5-ethyl-2-methylpyridin-3-yl)ethyl]-2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3h-pyran-6-one Chemical compound N1=C(N)C(CC)=CC(CCC2(OC(=O)C(CC3=NN4C(C)=CC(C)=NC4=N3)=C(O)C2)C2CCCC2)=C1C OBJZLLQBRVVCFZ-UHFFFAOYSA-N 0.000 claims 1
- NYHBKPWOGSMOKS-UHFFFAOYSA-N 2-[2-[2,6-bis(2,2,2-trifluoroethyl)pyridin-4-yl]ethyl]-2-cyclopentyl-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-3h-pyran-6-one Chemical compound N=1N2C=C(C)C=NC2=NC=1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCC1=CC(CC(F)(F)F)=NC(CC(F)(F)F)=C1 NYHBKPWOGSMOKS-UHFFFAOYSA-N 0.000 claims 1
- WUGYLLGNMCSUQM-UHFFFAOYSA-N 2-[3-chloro-5-[2-[2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3h-pyran-2-yl]ethyl]pyridin-2-yl]-2-methylpropanenitrile Chemical compound N1=C2N=C(C)C=C(C)N2N=C1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCC1=CN=C(C(C)(C)C#N)C(Cl)=C1 WUGYLLGNMCSUQM-UHFFFAOYSA-N 0.000 claims 1
- IDEGWCVLXNUCSN-UHFFFAOYSA-N 2-cyclopentyl-2-[2-(2,6-diethylpyridin-4-yl)ethyl]-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-3h-pyran-6-one Chemical compound CCC1=NC(CC)=CC(CCC2(OC(=O)C(CC3=NN4C=C(C)C=NC4=N3)=C(O)C2)C2CCCC2)=C1 IDEGWCVLXNUCSN-UHFFFAOYSA-N 0.000 claims 1
- XSJDVMHGTQZGEX-UHFFFAOYSA-N 2-cyclopentyl-2-[2-(2,6-dimethylpyridin-4-yl)ethyl]-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3h-pyran-6-one Chemical compound CC1=NC(C)=CC(CCC2(OC(=O)C(CC3=NN4C(C)=CC(C)=NC4=N3)=C(O)C2)C2CCCC2)=C1 XSJDVMHGTQZGEX-UHFFFAOYSA-N 0.000 claims 1
- KPAFBURYLWOICR-UHFFFAOYSA-N 2-cyclopentyl-2-[2-(2-ethyl-5-methoxypyridin-4-yl)ethyl]-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-3h-pyran-6-one Chemical compound C1=NC(CC)=CC(CCC2(OC(=O)C(CC3=NN4C=C(C)C=NC4=N3)=C(O)C2)C2CCCC2)=C1OC KPAFBURYLWOICR-UHFFFAOYSA-N 0.000 claims 1
- OOMDKIXNOABGDK-UHFFFAOYSA-N 2-cyclopentyl-2-[2-(2-ethyl-5-propoxypyridin-4-yl)ethyl]-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-3h-pyran-6-one Chemical compound CCCOC1=CN=C(CC)C=C1CCC1(C2CCCC2)OC(=O)C(CC2=NN3C=C(C)C=NC3=N2)=C(O)C1 OOMDKIXNOABGDK-UHFFFAOYSA-N 0.000 claims 1
- MHCUPLMWUDBQRC-UHFFFAOYSA-N 2-cyclopentyl-2-[2-(4-ethylpyridin-2-yl)ethyl]-4-hydroxy-5-[(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-3h-pyran-6-one Chemical compound CCC1=CC=NC(CCC2(OC(=O)C(CC3=NN4C=C(C)C=NC4=N3)=C(O)C2)C2CCCC2)=C1 MHCUPLMWUDBQRC-UHFFFAOYSA-N 0.000 claims 1
- AMRCSUYOSNECRQ-UHFFFAOYSA-N 2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-[2-(2-ethylpyridin-4-yl)ethyl]-4-hydroxy-3h-pyran-6-one Chemical compound C1=NC(CC)=CC(CCC2(OC(=O)C(CC3=NN4C(C)=CC(C)=NC4=N3)=C(O)C2)C2CCCC2)=C1 AMRCSUYOSNECRQ-UHFFFAOYSA-N 0.000 claims 1
- JVHCCHFIDUHSFQ-UHFFFAOYSA-N 2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-2-[2-(5-methoxy-2-methylpyridin-4-yl)ethyl]-3h-pyran-6-one Chemical compound COC1=CN=C(C)C=C1CCC1(C2CCCC2)OC(=O)C(CC2=NN3C(C)=CC(C)=NC3=N2)=C(O)C1 JVHCCHFIDUHSFQ-UHFFFAOYSA-N 0.000 claims 1
- LSVVRTCYQRPZKJ-UHFFFAOYSA-N 5-[(6-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-2-cyclopentyl-2-[2-(2-ethylpyridin-4-yl)ethyl]-4-hydroxy-3h-pyran-6-one Chemical compound C1=NC(CC)=CC(CCC2(OC(=O)C(CC3=NN4C=C(Cl)C=NC4=N3)=C(O)C2)C2CCCC2)=C1 LSVVRTCYQRPZKJ-UHFFFAOYSA-N 0.000 claims 1
- BXJRDNRTFGJWJN-UHFFFAOYSA-N 5-bromo-1-[2-[2-cyclopentyl-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3h-pyran-2-yl]ethyl]pyridin-2-one Chemical compound N1=C2N=C(C)C=C(C)N2N=C1CC(C(O1)=O)=C(O)CC1(C1CCCC1)CCN1C=C(Br)C=CC1=O BXJRDNRTFGJWJN-UHFFFAOYSA-N 0.000 claims 1
- SFSXNVBMAODLGN-UHFFFAOYSA-N Ethyl-2 methyl-6 pyridine Natural products CCC1=CC=CC(C)=N1 SFSXNVBMAODLGN-UHFFFAOYSA-N 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyrane Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60261804P | 2004-08-18 | 2004-08-18 | |
| PCT/IB2005/002697 WO2006018725A1 (en) | 2004-08-18 | 2005-08-05 | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110458T1 true HRP20110458T1 (hr) | 2011-07-31 |
Family
ID=35429645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110458T HRP20110458T1 (hr) | 2004-08-18 | 2011-06-17 | Inhibitori rna-ovisne rna-polimeraze iz virusa hepatitisa c, te pripravci i liječenje u kojem se koriste |
Country Status (43)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20094751B (en) * | 2004-08-18 | 2009-08-10 | Pfizer | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same |
| KR101064459B1 (ko) * | 2005-08-24 | 2011-09-16 | 화이자 인코포레이티드 | Ｈｃｖ 폴리머라제 억제제의 제조 방법 |
| MX2009011930A (es) | 2007-05-04 | 2009-11-18 | Vertex Pharma | Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c. |
| EP2008996A1 (en) * | 2007-06-27 | 2008-12-31 | Syngeta Participations AG | Process for the production of pyrazoles |
| WO2010002428A2 (en) | 2008-06-06 | 2010-01-07 | Scynexis, Inc. | Novel macrocyclic peptides |
| JP2011530562A (ja) | 2008-08-11 | 2011-12-22 | グラクソスミスクライン エルエルシー | アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体 |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| LT2320905T (lt) | 2008-08-11 | 2017-09-11 | Glaxosmithkline Llc | Naujieji adenino dariniai |
| UY32940A (es) | 2009-10-27 | 2011-05-31 | Bayer Cropscience Ag | Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas |
| EA201200650A1 (ru) | 2009-10-30 | 2012-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин |
| EP2325173A1 (de) | 2009-11-19 | 2011-05-25 | Bayer CropScience AG | Verfahren zum Herstellen von 5-Fluor-1-alkyl-3-fluoralkyl-1H-pyrazol-4-carbonsäurechloriden |
| CA2784646A1 (en) * | 2009-12-18 | 2011-06-23 | Boehringer Ingelheim International Gmbh | Hcv combination therapy |
| US8575340B2 (en) | 2010-02-10 | 2013-11-05 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
| CA2786973C (en) | 2010-02-10 | 2018-04-10 | Robert Hermann Gibbon | 6-amino-2-{[(1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate |
| ES2528646T3 (es) * | 2010-05-20 | 2015-02-11 | Bayer Intellectual Property Gmbh | Procedimiento para la fabricación de 1-alquil-3-difluorometil-5-hidroxipirazoles |
| US8987307B2 (en) | 2011-03-03 | 2015-03-24 | Hoffmann-La Roche Inc. | 3-amino-pyridines as GPBAR1 agonists |
| FR2972452B1 (fr) * | 2011-03-09 | 2013-03-15 | Rhodia Operations | Procede de preparation du difluoroacetonitrile et de ses derives |
| WO2013171134A1 (de) | 2012-05-14 | 2013-11-21 | Bayer Cropscience Ag | Verfahren zum herstellen von 1-alkyl-3-fluoralkyl-1h-pyrazol-4-carbonsäurechloriden |
| US9163027B2 (en) | 2012-11-21 | 2015-10-20 | Stategics, Inc. | Substituted triazolo-pyrimidine compounds for modulating cell proliferation differentiation and survival |
| US9932312B2 (en) | 2013-01-17 | 2018-04-03 | Bayer Cropscience Ag | Process for preparing 5-fluoro-1-methyl-3-difluoromethyl-1H-pyrazole-4-carbaldehyde |
| CA2900029C (en) | 2013-02-06 | 2021-03-02 | Bayer Cropscience Aktiengesellschaft | Halogen-substituted pyrazol derivatives as pest-control agents |
| RU2016131792A (ru) | 2014-01-03 | 2018-02-06 | Байер Энимэл Хельс ГмбХ | Новые пиразолил-гетероариламиды в качестве средств для борьбы с вредителями |
| JP6462703B2 (ja) | 2014-01-24 | 2019-01-30 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | １−アルキル−３−ジフルオロメチル−５−フルオロ−１ｈ−ピラゾール−４−カルバルデヒド類及び１−アルキル−３−ジフルオロメチル−５−フルオロ−１ｈ−ピラゾール−４−カルボキシレート類を調製する方法 |
| JP6452711B2 (ja) | 2014-02-20 | 2019-01-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | ヒトインターフェロンの誘導物質としてのピロロ［３，２］ピリミジン誘導体 |
| HUE040489T2 (hu) | 2014-06-03 | 2019-03-28 | Idorsia Pharmaceuticals Ltd | Pirazolvegyületek és alkalmazásuk t-típusú kalciumcsatorna-blokkolókként |
| CA2967248A1 (en) | 2014-11-13 | 2016-05-19 | Glaxosmithkline Biologicals Sa | Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions |
| WO2017093180A1 (de) | 2015-12-01 | 2017-06-08 | Bayer Cropscience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| EP3366691A1 (en) | 2015-12-03 | 2018-08-29 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
| KR102527786B1 (ko) | 2016-04-07 | 2023-04-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 단백질 조정제로서 유용한 헤테로시클릭 아미드 |
| CA3019628A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| US10660334B2 (en) | 2016-08-15 | 2020-05-26 | Bayer Cropscience Aktiengesellschaft | Fused bicyclic heterocycle derivatives as pesticides |
| EP3301094A1 (en) * | 2016-09-30 | 2018-04-04 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| TWI808952B (zh) | 2016-12-16 | 2023-07-21 | 瑞士商愛杜西亞製藥有限公司 | 包含t型鈣通道阻斷劑之醫藥組合 |
| MA47409A (fr) | 2017-02-06 | 2019-12-11 | Idorsia Pharmaceuticals Ltd | Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes |
| CN111433215B (zh) | 2017-10-04 | 2023-10-03 | 拜耳公司 | 用作害虫防治剂的杂环化合物的衍生物 |
| TW201927771A (zh) | 2017-10-05 | 2019-07-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 可作為蛋白質調節劑之雜環醯胺及其使用方法 |
| WO2019069270A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | GENERATOR STIMULATOR MODULATORS (STING) INTERFERON |
| CN111886238A (zh) | 2018-03-12 | 2020-11-03 | 拜耳公司 | 作为害虫防治剂的稠合双环杂环衍生物 |
| KR20210005081A (ko) | 2018-04-20 | 2021-01-13 | 바이엘 악티엔게젤샤프트 | 해충 방제제로서의 헤테로시클렌 유도체 |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| EP3969452A1 (en) | 2019-05-16 | 2022-03-23 | Stingthera, Inc. | Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use |
| US20220227761A1 (en) | 2019-05-16 | 2022-07-21 | Stingthera, Inc. | Oxoacridinyl acetic acid derivatives and methods of use |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| CN112194620B (zh) * | 2020-12-04 | 2021-02-26 | 苏州开元民生科技股份有限公司 | 一种2-乙基-4-氰基吡啶的制备方法 |
| CN113563167B (zh) * | 2021-07-16 | 2023-09-08 | 南通华祥医药科技有限公司 | 一种2-甲基-1-四氢萘酮的制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3786063A (en) * | 1971-05-24 | 1974-01-15 | Universal Oil Prod Co | Thiazolethiosulfonates |
| DE2155360C3 (de) * | 1971-11-08 | 1980-04-03 | Cassella Ag, 6000 Frankfurt | Verfahren zur Herstellung von Acylbernsteinsäuredialkylestern |
| CA1140049A (en) * | 1977-12-22 | 1983-01-25 | Dke J.E. Helgstran | Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid |
| US4326058A (en) * | 1979-02-05 | 1982-04-20 | Sumitomo Chemical Company, Limited | Organo-phosphoric esters and their production and use |
| US4489077A (en) * | 1983-03-23 | 1984-12-18 | Warner-Lambert Company | 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides |
| US6174868B1 (en) * | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| CA2167537A1 (en) * | 1993-07-19 | 1995-02-02 | Tsuneo Ozeki | Hepatitis c virus proliferation inhibitor |
| US5504104A (en) * | 1993-11-19 | 1996-04-02 | Warner-Lambert Company | Tricyclic pyrone derivatives as protease inhibitors and antiviral agents |
| US5808062A (en) * | 1993-11-19 | 1998-09-15 | Warner-Lambert Company | Pyrone derivatives as protease inhibitors and antiviral agents |
| HUT75225A (en) * | 1993-11-19 | 1997-04-28 | Parke Davis & Co | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents |
| JP3684426B2 (ja) | 1993-11-19 | 2005-08-17 | パーク・デイビス・アンド・カンパニー | プロテアーゼ阻害剤および抗ウイルス剤としての５，６−ジヒドロピロン誘導体 |
| US5840751A (en) * | 1993-11-19 | 1998-11-24 | Warner-Lambert Company | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents |
| US5834506A (en) * | 1996-11-01 | 1998-11-10 | Warner-Lambert Company | Dihydropyrones with improved antiviral activity |
| NZ510013A (en) | 1998-09-11 | 2003-11-28 | Warner Lambert Co | Dihydropyrones with selected heterocycles replacing the phenyls bearing polar substituents used as HIV protease inhibitors |
| US6512006B1 (en) * | 1999-12-09 | 2003-01-28 | Warner-Lambert Company | HIV protease inhibitors |
| EP1256628A3 (en) | 2001-05-10 | 2003-03-19 | Agouron Pharmaceuticals, Inc. | Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof |
| DOP2003000641A (es) * | 2002-05-10 | 2003-11-15 | Pfizer | Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan |
| US7148226B2 (en) * | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| GEP20094751B (en) * | 2004-08-18 | 2009-08-10 | Pfizer | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same |
-
2005
- 2005-08-05 GE GEAP20059868A patent/GEP20094751B/en unknown
- 2005-08-05 PT PT05775853T patent/PT1781662E/pt unknown
- 2005-08-05 ES ES05775853T patent/ES2361845T3/es active Active
- 2005-08-05 EP EP05775853A patent/EP1781662B1/en active Active
- 2005-08-05 AU AU2005273619A patent/AU2005273619B2/en not_active Ceased
- 2005-08-05 GE GEAP200510998A patent/GEP20115305B/en unknown
- 2005-08-05 CN CN2005800280919A patent/CN101006092B/zh not_active Expired - Fee Related
- 2005-08-05 UA UAA200700852A patent/UA88909C2/ru unknown
- 2005-08-05 DK DK05775853.4T patent/DK1781662T3/da active
- 2005-08-05 MX MX2007001527A patent/MX2007001527A/es active IP Right Grant
- 2005-08-05 WO PCT/IB2005/002697 patent/WO2006018725A1/en active Application Filing
- 2005-08-05 DE DE602005027580T patent/DE602005027580D1/de active Active
- 2005-08-05 AT AT05775853T patent/ATE506364T1/de active
- 2005-08-05 CN CN2009101381353A patent/CN101538268B/zh not_active Expired - Fee Related
- 2005-08-05 AP AP2007003918A patent/AP2313A/xx active
- 2005-08-05 CA CA2577525A patent/CA2577525C/en not_active Expired - Fee Related
- 2005-08-05 BR BRPI0514425-6A patent/BRPI0514425A/pt not_active IP Right Cessation
- 2005-08-05 EA EA200700338A patent/EA012605B1/ru not_active IP Right Cessation
- 2005-08-05 RS RS20110257A patent/RS51794B/en unknown
- 2005-08-05 KR KR1020077006118A patent/KR100851178B1/ko active IP Right Grant
- 2005-08-05 NZ NZ552874A patent/NZ552874A/en not_active IP Right Cessation
- 2005-08-05 SI SI200531314T patent/SI1781662T1/sl unknown
- 2005-08-05 PL PL05775853T patent/PL1781662T3/pl unknown
- 2005-08-05 JP JP2007526609A patent/JP4372195B2/ja not_active Expired - Fee Related
- 2005-08-12 MY MYPI20053809A patent/MY146123A/en unknown
- 2005-08-15 US US11/204,269 patent/US7151105B2/en not_active Expired - Fee Related
- 2005-08-15 PE PE2005000945A patent/PE20060677A1/es not_active Application Discontinuation
- 2005-08-15 UY UY29068A patent/UY29068A1/es not_active Application Discontinuation
- 2005-08-16 AR ARP050103438A patent/AR050699A1/es active IP Right Grant
- 2005-08-16 GT GT200500221A patent/GT200500221A/es unknown
- 2005-08-17 TW TW094128016A patent/TWI376379B/zh not_active IP Right Cessation
- 2005-08-17 NL NL1029755A patent/NL1029755C2/nl not_active IP Right Cessation
- 2005-08-18 HN HN2005000449A patent/HN2005000449A/es unknown
- 2005-08-18 SV SV2005002202A patent/SV2007002202A/es not_active Application Discontinuation
-
2006
- 2006-09-06 US US11/470,540 patent/US7622605B2/en not_active Expired - Fee Related
-
2007
- 2007-01-24 IL IL180933A patent/IL180933A/en not_active IP Right Cessation
- 2007-01-26 ZA ZA200700779A patent/ZA200700779B/xx unknown
- 2007-02-15 NI NI200700043A patent/NI200700043A/es unknown
- 2007-02-16 MA MA29684A patent/MA28803B1/fr unknown
- 2007-02-16 EC EC2007007264A patent/ECSP077264A/es unknown
- 2007-02-16 TN TNP2007000066A patent/TNSN07066A1/fr unknown
- 2007-02-16 CR CR8935A patent/CR8935A/es unknown
- 2007-03-08 NO NO20071274A patent/NO20071274L/no not_active Application Discontinuation
-
2008
- 2008-01-07 HK HK08100120.5A patent/HK1109617A1/xx not_active IP Right Cessation
- 2008-07-20 IL IL192919A patent/IL192919A0/en unknown
-
2009
- 2009-07-15 US US12/503,286 patent/US8268835B2/en not_active Expired - Fee Related
-
2011
- 2011-03-21 CR CR20110153A patent/CR20110153A/es unknown
- 2011-05-17 CY CY20111100486T patent/CY1111480T1/el unknown
- 2011-06-17 HR HR20110458T patent/HRP20110458T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110458T1 (hr) | Inhibitori rna-ovisne rna-polimeraze iz virusa hepatitisa c, te pripravci i liječenje u kojem se koriste | |
| JP7335003B2 (ja) | Ｓｈｐ２ホスファターゼアロステリック阻害物質 | |
| JP5911638B2 (ja) | ベンゾチアゾール−６−イル酢酸誘導体およびｈｉｖ感染を処置するためのそれらの使用 | |
| AU2016368317B2 (en) | Inhibitors of influenza virus replication, application methods and uses thereof | |
| RU2380101C2 (ru) | Бициклические пиримидины, ингибирующие hcv | |
| KR101967172B1 (ko) | 인플루엔자 바이러스 복제의 억제제 | |
| TW202122387A (zh) | Mta協同性之prmt5抑制劑 | |
| KR20150000871A (ko) | 4,4,-이치환-1,4-디하이드로피리미딘 및 b형 간염의 치료를 위한 약제로서 이의 용도 | |
| JP2020527588A5 (es) | ||
| EP3197883A1 (en) | Novel compounds | |
| KR102554019B1 (ko) | 인플루엔자 바이러스 복제의 억제제 및 이의 용도 | |
| CA2429728A1 (en) | Tyrosine kinase inhibitors | |
| JP2012501312A5 (es) | ||
| KR20120089648A (ko) | 결핵 억제제로서의 피리미딘 화합물 | |
| JP2012528166A5 (es) | ||
| RU2007130896A (ru) | Индольные производные для лечения вирусных инфекций | |
| KR20140024203A (ko) | 피리돈 및 아자-피리돈 화합물 및 사용 방법 | |
| JP2020527174A (ja) | Ａｔｒキナーゼの複素環式阻害剤 | |
| KR102440843B1 (ko) | Hiv 역전사효소 억제제의 전구약물 | |
| CN101918079A (zh) | 蛋白激酶抑制剂及其用途 | |
| JP2020527593A5 (es) | ||
| JP2021529815A (ja) | 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼ阻害剤 | |
| US20220340561A1 (en) | Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | |
| CA3213088A1 (en) | Substituted 1-aryl-1'-heteroaryl compounds, substituted 1,1'-biheteroaryl compounds, and methods using same | |
| RU2018124788A (ru) | Замещенные бензазиноны в качестве антибактериальных соединений |